Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta‐analysis

MLA

Wendy Allen‐Rhoades, et al. “Alveolar Rhabdomyosarcoma Has Superior Response Rates to Vinorelbine Compared to Embryonal Rhabdomyosarcoma in Patients with Relapsed/Refractory Disease: A Meta‐analysis.” Cancer Medicine, vol. 12, no. 9, May 2023, pp. 10222–29. EBSCOhost, https://doi.org/10.1002/cam4.5749.

APA

Wendy Allen‐Rhoades, Philip J. Lupo, Michael E. Scheurer, Yueh‐Yun Chi, John F. Kuttesch, Rajkumar Venkatramani, William H. Meyer, & Leo Mascarenhas. (2023). Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta‐analysis. Cancer Medicine, 12(9), 10222–10229. https://doi.org/10.1002/cam4.5749

Chicago

Wendy Allen‐Rhoades, Philip J. Lupo, Michael E. Scheurer, Yueh‐Yun Chi, John F. Kuttesch, Rajkumar Venkatramani, William H. Meyer, and Leo Mascarenhas. 2023. “Alveolar Rhabdomyosarcoma Has Superior Response Rates to Vinorelbine Compared to Embryonal Rhabdomyosarcoma in Patients with Relapsed/Refractory Disease: A Meta‐analysis.” Cancer Medicine 12 (9): 10222–29. doi:10.1002/cam4.5749.